Nikko Asset Management Americas’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-16,171
| Closed | -$12.5M | – | 196 |
|
|
2025
Q4 | $12.5M | Sell |
16,171
-4,053
| -20% | -$2.75M | 0.14% | 85 |
|
|
2025
Q3 | $11.4M | Sell |
20,224
-3,090
| -13% | -$1.75M | 0.11% | 89 |
|
|
2025
Q2 | $12.2M | Sell |
23,314
-850
| -4% | -$474K | 0.12% | 84 |
|
|
2025
Q1 | $15.3M | Sell |
24,164
-1,990
| -8% | -$1.37M | 0.2% | 73 |
|
|
2024
Q4 | $18.6M | Sell |
26,154
-2,730
| -9% | -$2.29M | 0.2% | 71 |
|
|
2024
Q3 | $30.4M | Sell |
28,884
-2,113
| -7% | -$2.35M | 0.34% | 55 |
|
|
2024
Q2 | $32.6M | Sell |
30,997
-2,308
| -7% | -$2.24M | 0.38% | 52 |
|
|
2024
Q1 | $32M | Sell |
33,305
-1,714
| -5% | -$1.63M | 0.32% | 57 |
|
|
2023
Q4 | $30.7M | Sell |
35,019
-1,733
| -5% | -$1.43M | 0.3% | 59 |
|
|
2023
Q3 | $30.2M | Sell |
36,752
-1,552
| -4% | -$1.22M | 0.36% | 53 |
|
|
2023
Q2 | $27.5M | Sell |
38,304
-21
| -0.1% | -$16.2K | 0.29% | 56 |
|
|
2023
Q1 | $30.6M | Sell |
38,325
-3,200
| -8% | -$2.41M | 0.35% | 46 |
|
|
2022
Q4 | $30M | Sell |
41,525
-933
| -2% | -$688K | 0.43% | 45 |
|
|
2022
Q3 | $29.4M | Sell |
42,458
-12,112
| -22% | -$7.62M | 0.38% | 52 |
|
|
2022
Q2 | $30M | Sell |
54,570
-14,667
| -21% | -$9.53M | 0.37% | 56 |
|
|
2022
Q1 | $47.1M | Sell |
69,237
-22,083
| -24% | -$14M | 0.35% | 57 |
|
|
2021
Q4 | $58M | Sell |
91,320
-30,552
| -25% | -$18.8M | 0.31% | 66 |
|
|
2021
Q3 | $70.3M | Sell |
121,872
-35,641
| -23% | -$22.1M | 0.3% | 63 |
|
|
2021
Q2 | $87.1M | Buy |
157,513
+77,895
| +98% | +$39.5M | 0.34% | 62 |
|
|
2021
Q1 | $37.7M | Buy |
79,618
+25,700
| +48% | +$12.5M | 0.18% | 89 |
|
|
2020
Q4 | $26M | Buy |
53,918
+25,546
| +90% | +$13.8M | 0.15% | 93 |
|
|
2020
Q3 | $15.9M | Sell |
28,372
-6,640
| -19% | -$4.03M | 0.14% | 94 |
|
|
2020
Q2 | $21.3M | Sell |
35,012
-26,634
| -43% | -$15.1M | 0.28% | 59 |
|
|
2020
Q1 | $30.1M | Sell |
61,646
-83,577
| -58% | -$34.5M | 0.56% | 47 |
|
|
2019
Q4 | $54.5M | Sell |
145,223
-14,330
| -9% | -$4.82M | 0.86% | 34 |
|
|
2019
Q3 | $44.3M | Buy |
159,553
+35,861
| +29% | +$10.6M | 0.79% | 41 |
|
|
2019
Q2 | $38.7M | Buy |
123,692
+100,668
| +437% | +$33.5M | 0.76% | 37 |
|
|
2019
Q1 | $9.45M | Buy |
+23,024
| New | +$9.48M | 0.25% | 66 |
|
|
2016
Q3 | – | Sell |
-1,000
| Closed | -$348K | – | 268 |
|
|
2016
Q2 | $348K | Buy |
1,000
+400
| +67% | +$154K | 0.03% | 182 |
|
|
2016
Q1 | $216K | Buy |
+600
| New | +$247K | 0.03% | 216 |
|
Other funds holding REGN
Nikko Asset Management Americas's REGN Position: Q1 2026 in Review
Nikko Asset Management Americas sold out of Regeneron Pharmaceuticals (REGN) in Q1 2026, closing a stake of 16,171 shares — an estimated $12.5M sold.
Nikko Asset Management Americas first reported a position in REGN in Q1 2016 and held it in 30 quarters. The position peaked at $87.1M in Q2 2021. 1,400 funds tracked by Wall St. Rank hold REGN as of Q1 2026.
- Nikko Asset Management Americas reported no remaining Regeneron Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
- Nikko Asset Management Americas sold 16,171 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $12.5M.
- Nikko Asset Management Americas first reported a position in Regeneron Pharmaceuticals in Q1 2016 and held it in 30 quarters.
- Nikko Asset Management Americas's Regeneron Pharmaceuticals position peaked at $87.1M in Q2 2021.
- 1,400 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.
Based on Nikko Asset Management Americas's 13F filing for Q1 2026, filed 7 May 2026.